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C1 domains mediate the recognition and subsequent signal-
ing response to diacylglycerol and phorbol esters by protein
kinase C (PKC) and by several other families of signal-transduc-
ing proteins such as the chimerins orRasGRP.MRCK (myotonic
dystrophy kinase-related Cdc42 binding kinase), a member of
the dystrophia myotonica protein kinase family that functions
downstream of Cdc42, contains a C1 domain with substantial
homology to that of the diacylglycerol/phorbol ester-responsive
C1 domains and has been reported to bind phorbol ester. We
have characterized here the interaction of theC1 domains of the
twoMRCK isoforms  andwith phorbol ester. TheMRCKC1
domains bind [20-3H]phorbol 12,13-dibutyrate with Kd values
of 10 and 17 nM, respectively, reflecting 60–90-fold weaker
affinity compared with the protein kinase C  C1b domain. In
contrast to binding by the C1b domain of PKC, the binding by
the C1 domains of MRCK  and  was fully dependent on the
presence of phosphatidylserine. Comparison of ligand binding
selectivity showed resemblance to that by the C1b domain of
PKC and marked contrast to that of the C1b domain of PKC.
In intact cells, as in the binding assays, the MRCK C1 domains
required 50–100-fold higher concentrations of phorbol ester
for induction of membrane translocation. We conclude that
additional structural elements within the MRCK structure are
necessary if the C1 domains ofMRCK are to respond to phorbol
ester at concentrations comparable with those that modulate
PKC.
sn-1,2-Diacylglycerol (DAG)2 is a central second messenger
in cells, generated through the receptor-mediated activation of
phosphatidylinositol 4,5-bisphosphate-specific phospholipase
C isoforms and indirectly through the action of phospholipase
D (1). The major recognition motif for DAG is a zinc finger
structure called a C1 domain (2–4). The C1 domains were first
shown to be responsible for the recognition of DAG and phor-
bol ester by the classical and novel protein kinase C (PKC) iso-
forms. Subsequently, homologous domains have been identi-
fied in some 50 different mammalian proteins.
Among these proteins, five families of proteins have been
shown to have C1 domains that in fact bind phorbol esters and
DAG (5). The protein kinase D family are kinases most closely
related to the myosin light chain kinases (6, 7). The chimerins
function as GTPase-activating proteins for Rac (8, 9). The Ras-
GRP family members function as guanyl nucleotide exchange
proteins for Ras and Rap1 (10). The Munc-13 family promote
vesicle fusion with membranes, enhancing synaptic transmis-
sion (11, 12). The DAG kinases phosphorylate DAG, terminat-
ing DAG signaling (13, 14).
Many other proteins have been described with C1 domains
that do not appear to respond to phorbol ester or DAG. Struc-
tural analysis suggests that these non-responsive C1 domains
can be divided into two groups. X-ray crystallographic and
NMR analysis, together with molecular modeling, have pro-
vided a detailed understanding of the interaction of phorbol
esters and DAGwith C1 domains (15). The phorbol ester binds
in a hydrophilic cleft in an otherwise hydrophobic surface at the
top of the C1 domain. By occupying this cleft, the phorbol ester
both completes the hydrophobic surface and contributes fur-
ther variable hydrophobic elements. Themajor class of phorbol
ester non-responsive C1 domains, exemplified by that of Raf,
shows modifications that disrupt this binding cleft. The C1
domains of the atypical PKCs, in contrast, appear to maintain
the structure of the binding cleft but have introduced residues
that destabilize membrane insertion and can interpose them-
selves in the binding cleft, competing for occupancy (16).
A C1 domain has been described in the MRCK isoforms 
and  (17). The MRCK (myotonic dystrophy kinase-related
Cdc42 binding kinase) isoforms are downstream effectors of
Cdc42, structurally related to the dystrophiamyotonica protein
kinase (DMPK) family, and function in actin cytoskeletal reor-
ganization. Tan et al. (18) have described that [20-3H]phorbol
12,13-dibutyrate (60 nM) was able to bind to MRCK and that
treatment of HeLa cells with phorbol 12-myristate 13-acetate
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(300 nM) followed by immune precipitation of the endogenous
MRCK enhanced the kinase activity of the immune precipi-
tatedMRCK formyosin light chain 2. In the present report, we
wished to characterize the phorbol ester responsiveness of the
C1 domains of MRCK  and  in more detail and to compare
them with the C1b domain of PKC, which is perhaps the C1
domain whose interactions with phorbol ester have been eval-
uated most extensively. We confirm that the C1 domains of
MRCK  and  recognize phorbol ester but their affinities both
when reconstituted in phospholipid vesicles and in intact cells
are substantially weaker than that of the C1b domain of PKC.
EXPERIMENTAL PROCEDURES
Materials—[20-3H]Phorbol 12,13-dibutyrate ([3H]PDBu)
(17 Ci/mmol) was purchased from PerkinElmer. 1,2-Di-
octanoyl glycerol was purchased from Sigma. The DAG lac-
tones HK-434 and 130C045 were synthesized as described pre-
viously (26, 27). PDBu and phorbol 12-myristate 13-acetate
(PMA) were purchased from LC Laboratories (Woburn, MA).
Phosphatidyl-L-serine was purchased from Avanti Polar Lipids
(Alabaster, AL). Reagents for expression and purification of
glutathione S-transferase (GST) fusion proteins were obtained
from Pierce Biotechnology. Cell culture medium, reagents, and
all DNA primers were obtained from Invitrogen.Mousemono-
clonal anti-GFP antibody was purchased from Roche Applied
Science. Rabbit polyclonal anti-PKC antibody was purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
mouse IgG was purchased from Bio-Rad.
Construction of GST- and GFP-fused C1 Domains ofMRCK
andMRCK—The C1 domains of MRCK  and  were gener-
ated byPCRusing the PlatinumPfxDNApolymerase (Invitro-
gen). The full-length cDNA clones of Homo sapiens myotonic
dystrophy kinase-related CDC42-binding protein kinase 
(DMPK-like) (MRCK) and H. sapiens myotonic dystrophy
kinase-related CDC42-binding protein kinase  (DMPK-like)
(MRCK) were used as the templates. The following oligonu-
cleotides were used as the PCR primers to pull out the targeted
C1 domains: (i) forward and reverse primers for the C1 domain
of MRCK were 5-CGG GAT CCA GCC TGG TTC AAC
TGG CTT T-3 and 5-CGG TCG ACG TCA TGT TCC TAT
TCCTTTCTG-3 (3905–3953); (ii) forward and reverse prim-
ers for MRCK were 5-AT G AA T TC AGG CCC TGG CTC
TGG C-3 and 5-AT GTC GAC T GCA CGT CCA CGC
CCA-3 (3330–3561). The C1 domains of MRCK  and were
subcloned into the pGEX vector to produce GST fusion pro-
teins in Escherichia coli strain BL21. To produce a construct
suitable for mammalian expression and confocal studies, the
cDNAs of the C1 domains of MRCK  and were amplified by
PCR and subcloned into the pEGFP vector (Clontech, Palo
Alto, CA). TheDNA sequence of each construct was confirmed
by sequencing analysis (DNA Minicore, Center for Cancer
Research, NCI, National Institutes of Health).
Expression in E. coli and Purification of the C1 Domains of
MRCK  and —The recombinant plasmids of the individual
C1 domains of MRCK  and  were transformed into BL-21-
Gold (DB3) E. coli strain BL21. The expression of the GST
fusion proteins was induced with 0.5 mM isopropyl-O-D-thio-
galactopyranoside that was added when the optical density of
the Luria Bertani medium containing bacteria (Quality Biolog-
ical, Inc., Gaithersburg, MD) reached 0.5–0.7. The bacteria
were harvested after 4 h of induction at 37 °C. The expressed
GST-tagged C1 protein was purified using a B-PER GST spin
purification kit (Pierce). The purified GST-C1 proteins were
stored in 30% glycerol at70 °C.
Measurement of [3H]PDBu Binding—[3H]PDBu binding to
the C1 domains ofMRCK/ and PKC/wasmeasured using
the polyethylene glycol precipitation assay developed in our
laboratory (19) with minor modifications. Briefly, the assay
mixture (250 l) containing 50 mM Tris-Cl, pH 7.4, 100 g/ml
phosphatidylserine, 4 mg/ml bovine immunoglobulin G, 0.1
mM CaCl2, and various concentrations of [3H]PDBu was incu-
bated at 18 °C for 10 min in 1.5-ml microfuge tubes. Samples
were then chilled on ice for 7 min, 200 l of 35% polyethylene
glycol in 50 mM Tris-Cl, pH 7.4, was added, and the samples
were mixed and incubated on ice for an additional 10 min. The
tubes were then centrifuged in a Beckman Allegra 21R centri-
fuge at 4 °C (12,200 rpm, 15min). A 100-l aliquot of the super-
natant from each tube was removed for determination of the
free concentration of [3H]PDBu; the remaining supernatant
was discarded, and the pellet was carefully dried. The tip of the
centrifuge tube containing the pellet was cut off and transferred
to a scintillation vial for the determination of the total bound
[3H]PDBu. Radioactivity was determined by scintillation
counting. Nonspecific binding was determined in the presence
of 30 M non-radioactive PDBu. Specific binding was calcu-
lated as the difference between total and nonspecific binding.
To measure competition of [3H]PDBu binding by different
compounds, assays were performed under similar conditions
but using a fixed concentration of [3H]PDBu and increasing
concentrations of the nonradioactive ligand. In a typical com-
petition assay, six to eight different concentrations of the com-
peting ligand were used. Standard Scatchard analysis was per-
formed to determine the dissociation constants (Kd) of the
individual C1 domains, and the inhibitory dissociation con-
stants (Ki) were calculated using our standard method as
described previously (19). Binding data of 1,2-dioctanoyl glyc-
erol to the C1 domain of PKC were analyzed by the modified
Hill equation. Values of specific binding were determined in
triplicate at each ligand concentration in each experiment. All
binding experiments were performed at least three times unless
otherwise specified.
Expression and Imaging of GFP-tagged C1 Domains in Living
Cells—LNCaP cells (obtained from ATCC, Manassas, VA)
were cultured at 37 °C in RPMI 1640 containing 10% fetal
bovine serum, penicillin (50 units/ml), and streptomycin (0.05
mg/ml) in a 5% CO2 atmosphere. The plasmid DNAs of the
GFP-fused individual C1 domain of MRCK and the C1b
domain of PKCwere transfected into LNCaP cells using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. The translocation ofC1domainswas determined 24h
after transfection. Cells were examined with a Zeiss LSM 510
confocal microscope (Carl Zeiss Inc., Thornwood, NY) with an
Axiovert 100 M inverted microscope operating with a 25-mil-
liwatt argon laser tuned to 488 nm. Cells were imaged with a
63  1.4 NA Zeiss Plan-Apochromat oil immersion objective
and with varying zooms (1.4–2). Time lapse images were col-
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lected before and after administration of PMA every 30 s using
the Zeiss AIM software, in which the green emission was col-
lected in a photomultiplier with an LP 505 filter.
Preparation of Cell Fractions and Immunoblot Analysis of
Membrane Translocation of the C1 Domain of MRCK and the
C1b Domain of PKC in LNCaP Cells—LNCaP cells (obtained
from ATCC) were seeded in 60-mm Petri dishes. 24 h after
transfectionwith the C1 domain ofMRCK or the C1b domain
of PKC, the cells were treated with PMA (0.001–30M) for 30
min. The cells were washed with ice-cold Dulbecco’s phos-
phate-buffered saline (KD Medical, Inc., Columbia, MD) and
then harvested with 120 l of 50 mM Tris-HCl, pH 7.4, plus
protease inhibitor mixture (Roche Applied Science). Cells were
frozen for 1 min in a dry ice-ethanol mixture and subsequently
thawed for 1min in a 37 °Cwater bath; the processwas repeated
eight times. 100 l of the cell lysate was transferred to a Beck-
man ultracentrifuge tube and centrifuged at 200,000 g for 2 h
to separate the cytosolic and membrane fractions; the remain-
ing 20 l was used as the total cell fraction. After ultracentrif-
ugation, the supernatant was designated as the cytosolic frac-
tion. The pellet was resuspended in 100l of lysis buffer (50mM
Tris-Cl, pH 7.4, protease inhibitor mixture, and 1% Nonidet
P-40) (Calbiochem) and incubated on ice for 1 h. This mixture
was again subjected to centrifugation (100,000 g for 1 h). This
supernatant was designated as the membrane fraction. Each
sample were diluted in 2 SDS buffer and boiled 10 min on
100 °C. An equal volume of sample (18l) for each fraction was
subjected to SDS-polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulosemembranes. After themembranes were
blocked with 5% nonfat milk in phosphate-buffered saline for
1 h, the blots were probed with anti-GFP monoclonal antibody
(Roche Applied Science) and the appropriate secondary anti-
body. The signal was developed by enhanced chemilumines-
cence (ECL) (Amersham Biosciences) and imaged on BioMax
MAX films (Kodak). Bands were quantified densitometrically
using ImageJ software (NIH Image). In a typical membrane
translocation assay, ten concentrations of ligand were used.
RESULTS
Binding of Phorbol Esters to the Recombinant C1 Domains of
MRCK and MRCK—The structures of MRCK  and  (20)
are shown schematically in Fig. 1A. Both MRCK isoforms con-
tain C1 domains that show high sequence homologywith phor-
bol ester binding C1 domains in PKC isoforms (Fig. 1B), and
indeed the C1 domain of MRCK was shown directly to bind
phorbol ester although it was not further evaluated (18). We
wished to determine the binding characteristics of the C1
domains of these proteins for direct comparison with the well
characterized domains of protein kinase C isoforms.
The isolatedC1domains ofMRCK andwere expressed as
GST fusion proteins inE. coli and partially purified as described
under “Experimental Procedures.” [3H]PDBu binding was
measured in the presence of 100 g/ml of phosphatidylserine.
As is the case for theC1 domains of protein kinase C, [3H]PDBu
(20 nM) bound rapidly to the C1 domains of MRCK  and ; a
maximal level of binding was obtained between 10 and 15 min
(data not shown) at 18 °C and slowly decreased thereafter. A
similar level of binding was observed at 0 °C (a single experi-
ment), whereas binding at 37 °C was substantially less. For sub-
sequent analysis, we therefore used a 10-min incubation time at
18 °C.
Under these conditions, Scatchard analysis revealed that C1
domains of MRCK  and  bound [3H]PDBu with dissociation
constants (Kd values) of 10.3 2.0 and 17 1.2 nM, respectively
(mean  S.E., n  3 experiments), in the presence of 0.1 mM
FIGURE 1. Structures of MRCK  and . A, schematic structures of MRCK 
and . CC, coiled-coil; C1, cysteine-rich domain; PH, pleckstrin homology
domain; CH, citron homology domain; PBD, p21 GTPase binding domain.
B, comparison of the C1 domains of MRCK  and  and the C1b domains of
PKC  and .
TABLE 1
Structure-activity analysis of binding to the C1 domain of MRCK /, PKC C1b, and PKC C1b
TheKd values for PDBu binding weremeasured directly with [3H]PDBu. The ID50 values for the other compounds were determined from competition curves for inhibition
of [3H]PDBubinding, and the correspondingKi valueswere calculated as indicated under “Experimental Procedures.” Values represent themean S.E. of three experiments
per group.1, from Ref. 26. *, calculated using the modified Hill equation.
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CaCl2. These values were 58- and 96-fold weaker than that for
the C1b domain of PKC (Kd  0.18  0.004 nM) and 3- and
5-fold weaker than for the C1b domain of PKC (Kd  3.4 
0.12 nM) (mean S.E.,n 3, experiments performed in parallel
for the C1 domains of PKC, MRCK, and MRCK) (Table 1;
supplemental Fig. S1). These results confirm that the C1
domains are able to bind phorbol ester but suggest that the
binding affinities, at least of the isolated C1 domains, are appre-
ciably weaker than those of the C1b domain of PKC  or .
PDBu Binding to the C1 Domains of MRCK andMRCK as
a Function of Phosphatidylserine Concentration and the Total
Amount of Phospholipids—Acidic phospholipids are essential
cofactors for the activation of PKC (21), with phosphatidyl-
serine being the most effective phospholipid for supporting
phorbol ester/DAG binding to PKC, n-chimerin, and Unc-13
(22–24). Because of the relatively low affinity binding of
[3H]PDBu to the C1 domains of MRCK  and , we wished to
determine whether some lipid conditions other than those
selected would lead to enhanced affinities. In the first series of
experiments, we determined the specific binding of [3H]PDBu
to theMRCKC1 domain as a function of total phospholipid at
various fixed proportions of phosphatidylserine (Fig. 2A).
Under all conditions, the [3H]PDBu binding was dependent on
the presence of phospholipid. It also showed amarked depend-
ence on phosphatidylserine and, at high proportions of phos-
phatidylserine, showed inhibition at excess amounts of total
lipid. Under our standard conditions of 100% phosphatidyl-
serine, the level of binding was optimal at 100 g/ml phospho-
lipid and decreased at higher concentrations. In contrast, at
20% phosphatidylserine maximal binding was only achieved at
1000 g/ml total lipid.
A similar patternwas observedwhen the proportion of phos-
phatidylserine was varied at various fixed amounts of total
phospholipid (Fig. 2B). At 100 g/ml of total phospholipid,
maximal binding was seen at 75% or more phosphatidylserine.
In contrast, at 1000 g/ml total phospholipid, optimal
[3H]PDBu binding was observed at 25% phosphatidylserine,
with decreasing binding at either higher or lower proportions.
In single experiments, we obtained similar results for the C1
domain of MRCK, both for the optimal amount of total phos-
pholipid at 20 and 80% phosphatidylserine and for the optimal
% phosphatidylserine at 300 and 1000 g/ml total phospho-
lipid. We conclude that the requirements of the C1 domains of
MRCK for phosphatidylserine are appreciably higher than that
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FIGURE 2.Effect of phospholipid compositionon [3H]PDBubinding to theC1domainofMRCK.Binding of specific [3H]PDBu (9 nM)was performed in the
presence of 0.1 mM CaCl2 and increasing concentrations of PS:PC (100:0, 80:20, or 20:80, as indicated) (A) or increasing proportions of PS in PS:PCmixtures at total
amounts of phospholipid of 100, 300, or 1000g/ml (B). Values represent themeanof four independent experiments. S.E. values are representedby the error bars. In
each individual experiment, themaximalmean specific [3H]PDBubindingvalue for a specific lipid conditionwas set to100%and themean specific [3H]PDBubinding
valuesunder theother lipidconditionswerenormalizedtothatvalue.Because inthereplicateexperiments inB thesameproportionofPSdidnotalways represent the
optimal binding condition, themaximalmean valueswere consequently not always 100%. PS, phosphatidylserine; PC, phosphatidylcholine.
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of the PKC C1b domain, which retains 50% of maximal bind-
ing in the absence of phosphatidylserine at 100 g/ml total
phospholipid (16). Furthermore, our binding conditions appear
appropriate and do not readily explain the relatively low affinity
observed for the C1 domains of MRCK  and .
Structure Activity Analysis of Binding to the C1 Domain of
MRCK/—Different C1 domains show different patterns of
ligand recognition (25, 26). For comparison of the ligand selec-
tivity of the C1 domains ofMRCK andwith that of other C1
domains, we performed competition binding studies using sev-
eral structurally diverse, high affinity ligands for other C1
domains (Table 1). Competition experiments with the DAG
lactone HK-434 (27) revealed 1000-fold lower affinities for
MRCK  and  than for the C1b domain of PKC but only
2.5-fold weaker affinity than for the C1b domain of PKC (sup-
plemental Fig. S2). The results for 1,2-dioctanoyl glycerol, for
the DAG lactone 130C045 (26), and for sapintoxin D revealed a
similar pattern. Both the C1 domains ofMRCK and and the
C1b domain of PKC bound 1,2-dioctanoyl glycerol with 400–
1000-fold weaker affinity than did the C1b domain of PKC. Of
incidental note, the measurement of the binding affinity of 1,2-
dioctanoyl glycerol to the C1b domain of PKC should be con-
sidered approximate because of non-theoretical behavior,
probably reflecting a secondary effect of enhanced PDBu affin-
ity as 1,2-dioctanoyl glycerol partitions into the phosphatidyl-
serine in the assay. The C1 domain ofMRCK  and  displayed
15,000-foldweaker binding of 130C045 than did theC1 domain
of PKC, compared with only 5–6-fold weaker binding relative
to the C1b domain of PKC. For sapintoxin D, the C1 domains
of MRCK  and  indeed bound with modestly higher affinity
than did the C1b domain of PKC, whereas once again the C1b
domain of PKC bound with 40–90-fold stronger affinity. We
conclude that the C1 domains of MRCK  and  show ligand
selectivity similar to the C1b domain of PKC, at least for this
series of ligands. Relative to the C1b domain of PKC, the C1
domains ofMRCK and bind the other ligands examined not
appreciably better than they do PDBu, and they bind diacylg-
lycerol, the physiological ligand, markedly more poorly.
Comparison of Translocation to the Membrane of the C1
Domain ofMRCK and theC1bDomain of PKC in Response to
PMA—We were concerned that the apparent weak affinity of
the C1 domain of MRCK for phorbol ester might reflect an
inappropriate environment under our assay conditions, despite
our efforts to optimize the lipid conditions.We therefore exam-
ined the ability of the C1 domain of MRCK to undergo trans-
location from the cytosol to the membrane as a function of
phorbol ester concentration and compared its sensitivity with
that of theC1bdomain of PKC.Weprepared theC1domain of
MRCK as a fusion construct with GPF and expressed it in the
LNCaP human cell line. The transfected LNCaP cells were
treated with various doses of PMA (0.001–30 M) for 30 min,
after which the cells were harvested, membrane and cytoplas-
mic fractions were prepared, and the distribution of the C1
domain of MRCK between cytosolic and membrane fractions
was determined by Western blotting using anti-GFP antibody
(Fig. 3A). Translocation required 1–30 M PMA, in contrast to
a concentration of 0.01–0.03 M PMA for the C1b domain of
PKC (Fig. 3B). We conclude that, in intact cells as in the in
vitro binding assays, the response of the C1 domain of MRCK
was 100–1000-fold weaker than that of the C1b domain of
PKC.
Comparison of the Redistribution of the C1 Domain of
MRCK and the C1b Domain of PKC in LNCaP Cells after
Phorbol Ester Treatment—Using the GFP fusion protein with
the C1 domain of MRCK, we also examined its subcellular
distribution in living LNCaP cells as a function of time after
treatment with various doses of PMA and compared its
response with that of the C1b domain of PKC. The cells were
maintained at room temperature and imaged with a Zeiss LSM
510 confocal microscope. Under control conditions, most of
the C1 domain of MRCK was present in the cytoplasm of the
cells with lower amounts in the nucleus and perhaps a small
amount associated with the plasma membrane (Fig. 4A). Addi-
tion of PMA led to a slow, concentration-dependent shift in the
distribution of the MRCK C1 domain. Translocation only
began to be observed at concentrations of PMA of 0.5 M and
higher. Translocationwas to the plasmamembrane, with loss of
MRCKC1 domain from the nucleus also being evident. In con-
trast, the C1b domain of PKC showed slow translocation at
0.01 M PMA and a more rapid response at higher concentra-
tions of PMA (Fig. 4B). We conclude that the C1 domain of
MRCK was 50–100-fold less responsive to PMA under
these conditions in living cells. Similar results were obtained
with measurements conducted at 37 °C (data not shown).
DISCUSSION
Our analysis confirms the findings of Tan et al. (18) that
MRCK  and  represent the seventh class of proteins with
phorbol ester-responsive C1 domains, along with PKC, protein
kinase D, the chimerins, RasGRP, munc-13, and the DAG
FIGURE 3. Induction of translocation by PMAof the C1 domain ofMRCK
and the C1b domain of PKC in LNCaP cells. LNCaP cells were transfected
with theGFP-taggedC1domainofMRCK (A) or theGFP-taggedC1bdomain
of PKC (B) and treated with the indicated concentrations of PMA (0.001–30
M) for 30 min. Cells were then fractionated by ultracentrifugation into cyto-
solic andmembrane fractions as describedunder “Experimental Procedures.”
Aliquots of the different fractions were subjected to electrophoresis on SDS-
polyacrylamide gels and Western blotting with anti-GFP antibody. Similar
results were obtained in four additional independent experiments.
C1 Domain ofMRCK as a Phorbol Ester Receptor
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FIGURE 4. Subcellular redistribution of the GFP-tagged C1 domain of MRCK following PMA treatment in living LNCaP cells. LNCaP cells were tran-
siently transfected with the GFP-tagged C1 domain of MRCK (A) or the GFP-tagged C1b domain of PKC (B). Live cells were treated for 20 or 40 min with
different concentrations of PMA (0.01–6 M), and the translocation of the green fluorescent proteins was recorded as a function of time after the addition of
compound using a Zeiss LSM 510 laser-scanning confocal microscope as indicated under “Experimental Procedures” (scale bar on each figure represents 10
m). The time in each panel represents the period after the drug administration. Images are from single, representative experiments. Each experiment was
repeated at least three additional times with similar results.
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kinases. MRCK thus provides yet another divergent pathway
for phorbol ester action. The interactions of phorbol esterswith
the pathways involving the small GTPases are extensive. The
chimerins function as GTPase-activating proteins for Rac,
reducing Rac activity. The RasGRP proteins function as GTP
exchange factors for Ras and Rap, enhancing their activity. PKC
activates RasGRP1/3 by phosphorylation and has additional
effects downstream of Ras. Finally, the MRCK proteins func-
tion downstream of Cdc42. One of the very early observations
about the response of cultured cells to phorbol esters was their
dramatic effect on cellular morphology (28). The identification
of the multiple targets of phorbol ester action involved in
aspects of morphology emphasizes the complexity underlying
this observation.
The C1 domains ofMRCK  and  provide further examples
of the diversity of behavior within C1 domains. The differences
for the binding affinity of PDBu are in general larger than those
reported by Irie et al. (25) among the C1 domains from previ-
ously characterized families of phorbol ester receptors. As
observed by us and others, different C1 domains differ in their
ligand selectivities (25, 26). Thus, for example, 130C037 has a
Kd of 1.8 nM for the C1b domain of PKC and a value of10M
for that of PKC. Likewise, depending on the ligand, the differ-
ence in selectivity between the C1 domain of MRCK and the
C1b domain of PKC ranged from 42-fold for sapintoxin D to
15000-fold for 130C045. These results argue that it is not sim-
ply that theMRCKC1 domains have low affinity for ligands but
rather that they show altered structure activity relations.
The context in which the C1 domains are present plays an
important role in their function. Canacarajah et al. (29) have
elegantly demonstrated with 2-chimerin that the C1 domain
is shielded by other residues in the intact protein and that
unfolding of the protein markedly enhances the potency of
phorbol ester for inducing translocation. Less direct studies
suggest a similar situation for the PKCs (30). For the PKCs, a
mechanistic basis for such effects is the presence of othermem-
brane- or ligand-interacting domains, for example the C2
domains of the classical PKCs that contribute, along with phor-
bol ester binding to the C1 domain, to the overall energetics of
membrane association (31). Thus, whereas the C1b domain of
PKC binds the selective constrained DAG lactone 130C037
with 300-fold higher affinity than does either of the two isolated
C1 domains of PKC, the intact PKC binds 130C037with only
4-fold stronger affinity than does intact PKC (26).Our present
results withMRCK argue that other structural elements will be
needed to drive a robust response to phorbol ester or
diacylglycerol.
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